Fig. 1From: Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the artPie chart depicting the current application of subconjunctival injections in clinical trials (clinicaltrials.gov). Macular edema (9%), blepharoptosis (3%), cornea regeneration (MSC transplantation) (14%), neovascularization (20%), pterygium (9%), glaucoma (12%), dry eye (3%), burn (use of vitamin C) (3%), age-related macular degeneration (AMD) (3%), cataract (9%), uveitis (3%), keratitis (3%), bleb (3%), and anesthesia (6%)Back to article page